Genzyme acquires SangStat Medical

FRAMINGHAM (09/24/2003) - In a US$600-million deal set to close this month, Genzyme Corp. will acquire SangStat Medical Corp. A global biotechnology company focused on immunology, SangStat's pipeline complements Genzyme's work in immune-mediated diseases. The $22.50-per-share transaction amount represents an approximately 45-percent premium over the closing price of SangStat's shares on Aug. 1.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

More about SangStat Medical

Show Comments